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Abstract
Background: Primary radiochemotherapy with photons is the standard treatment for locally advanced-stage non-small
cell lung cancer (NSCLC) patients. Acute radiation-induced side effects such as oesophagitis and radiation pneumonitis
limit patients’ quality of life, and the latter can be potentially life-threatening. Due to its distinct physical characteristics,
proton therapy enables better sparing of normal tissues, which is supposed to translate into a reduction of
radiation-induced side effects.
Methods/design: This is a single-centre, prospective, randomised controlled, phase II clinical trial to compare
photon to proton radiotherapy up to 66 Gy (RBE) with concomitant standard chemotherapy in patients with
locally advanced-stage NSCLC. Patients will be allocated in a 1:1 ratio to photon or proton therapy, and treatment
will be delivered slightly accelerated with six fractions of 2 Gy (RBE) per week.
Discussion: The overall aim of the study is to show a decrease of early and intermediate radiation-induced toxicity
using proton therapy. For the primary endpoint of the study we postulate a decrease of radiation-induced side effects
(oesophagitis and pneumonitis grade II or higher) from 39 to 12%. Secondary endpoints are locoregional and distant
failure, overall survival and late side effects.
Trial registration: Registered at ClinicalTrials.gov with Identifier NCT02731001 on 1 April 2016.
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Background
Primary lung tumours are a leading cause for tumour-
related mortality worldwide, which is mainly due to their
unfavourable prognosis, particularly in the advanced or
metastasised stages. Non-small cell lung cancer (NSCLC)
accounts for the vast majority of primary lung cancers. The
treatment of choice for inoperable or locally advanced
NSCLC without distant metastasis is primary radiochemo-
therapy [1]. The prescribed standard radiation dose ranges
between 60 and 66 Gy in 2-Gy fractions, delivered using
three-dimensional conformal or intensity-modulated radi-
ation therapy (3D-CRT and IMRT, respectively). As local
failure occurs in about 50% of patients with locally ad-
vanced disease, current approaches aim for escalation of ra-
diation dose. The phase III RTOG 0617 trial randomised
patients to 60 Gy standard dose or 74 Gy dose escalation
after promising phase I and II trials [2]. Unexpectedly, me-
dian overall survival of patients in the high-dose group was
decreased compared to standard fractionation. The under-
lying reasons are currently being assessed and may include
insufficient target coverage and increased dose to the heart.
In general, pulmonary, oesophageal and cardiac toxicity
[3] constitute the most relevant acute and late toxicities
after thoracic radiotherapy. Therefore, future studies on im-
proved radiation treatment for NSCLC have to include
vigorous reduction of normal tissue complication probabil-
ities. One promising approach is the use of proton beam
radiotherapy. Proton therapy offers advantages in normal
tissue sparing due to the sharp dose fall-off behind the tar-
get volume covered by the spread-out Bragg peak that it
produces. In a retrospective analysis, patients with ad-
vanced stages of NSCLC treated with proton beam therapy
presented with fewer radiation-induced side effects al-
though they were treated with 74 Gy (RBE) (= photon
equivalent dose by considering an average relative biological
effectiveness (RBE) of 1.1) compared to the photon control
group which had a prescribed dose of only 63 Gy [4]. Proton
therapy offers unique opportunities for dose escalation in
NSCLC due to its sparing of low and intermediate radiation
doses to surrounding normal tissues. Before applying dose
escalation with proton beam therapy, prospective studies
confirming lower normal tissue toxicity for proton therapy
should be performed to ensure maximum patient safety.
The aims of the present study are to demonstrate a re-
duction of acute radiation-induced side effects, i.e. pneu-
monitis and oesophagitis grade II or higher, using proton
versus photon radiochemotherapy to equal radiation
doses. Secondary endpoints include evaluation of quality
of life, locoregional control, occurrence of distant metasta-
ses, survival and late radiation-induced side effects.
Methods/design
This is a single-centre, prospective, randomised con-
trolled, phase II clinical trial comparing slightly
accelerated radiochemotherapy with photons to that
with protons in patients with inoperable or locally ad-
vanced, cytologically or histologically confirmed NSCLC.
Dose prescription to the tumour is 66 Gy (RBE), maximal
doses to the organs at risk comply with international stan-
dards. All patients undergo complete clinical staging with
Fluorodeoxyglucose-Positron Emission Tomography-
Computer Tomography (FDG-PET-CT) and magnetic
resonance imaging (MRI) of the brain.
Inclusion criteria
 NSCLC (confirmed by cytology or histology) staged
UICC IIIA or IIIB or UICC II if the tumour is
medically inoperable or the patient declines surgery
 No distant metastases (M1)
 Patient is aged between 18 and 70 years
 Patient is medically suited for primary
radiochemotherapy with curative intent
 Patient has signed a declaration of informed consent
 Adequate compliance for treatment and clinical
follow-up
 Adequate contraception during and after therapy
if indicated
Exclusion criteria
 Participation in another interventional trial at the
same time
 T1 or T2 N0 tumours that are suitable for
stereotactic radiotherapy
 Relevant neurological or psychiatric disorders that
hinder treatment, follow-up or understanding of
the procedures
 Pregnant or breastfeeding women
 Prior thoracic radiotherapy
 History of other malignancies during the last 5 years
(exceptions can be made for tumours with excellent
outcome)
 Unintended weight loss greater than 15% before
therapy
 Serological alterations (liver, kidney) prohibiting
application of simultaneous chemotherapy
 Respiratory motion of the tumour of more than
10 mm (evaluated by four-dimensional computer
tomography (4D-CT), also when methods for motion
reduction (abdominal compression) are applied
Recruitment, randomisation and workflow
To assess whether patients can be treated with protons,
a 4D-CT will be performed to evaluate the respiratory
motion of the tumour. If tumour motion is larger than
10 mm, abdominal compression or gating methods can
be used and the patient will undergo a second 4D-CT
Zschaeck et al. Trials  (2016) 17:543 Page 2 of 7
scan. If the respiratory motion is still too large, the pa-
tient will be treated with photons within an observa-
tional cohort. For patients with tumour motion of less
than 10 mm, the gross tumour volume (GTV), clinical
target volume (CTV) and organs at risk (OAR) will be
delineated. Patients are then randomised for proton or
photon therapy and the respective radiation plans will
be calculated. If target coverage is insufficient or doses
at OAR are too high, a new treatment plan using the
other modality (photons or protons respectively) will be
calculated. If the other plan adheres better to the con-
straints, the patient is treated with the respective modality
within an observational cohort. Patient reallocation to an-
other treatment arm due to nonconformity to the con-
straints will be statistically handled as an event in the
randomised (intent-to-treat) arm. This procedure ensures
maximum patient safety while not compromising results
for randomised patients. Figure 1 shows a flowchart of
patient allocation to treatment arms.
Radiotherapy
Treatment is planned using FDG-PET-CT in the treat-
ment position and an additional 4D-CT to assess tumour
motion. On the basis of the 4D-CT an internal gross
tumour volume (iGTV) is generated that encompasses the
whole tumour motion during respiration. The CTV is
generated by summing the iGTVs. Patients within the
photon arm will be treated using IMRT with six fractions
per week to a total dose of 66 Gy. Patients within the
proton arm will receive 66 Gy (RBE) also delivered with
six fractions per week. Target coverage and dose to organs
at risk will be assessed by at least one physician and one
physicist. Constraints will be according to current clinical
guidelines in combination with the RTOG 1308 con-
straints, whichever is stricter than the QUANTEC cri-
teria [5]. During the course of radiotherapy in-room
control 4D-CTs (maximum two per week) will be ac-
quired to check for stability of inner anatomy and motion
characteristics.
Chemotherapy will be delivered according to current
clinical standards without differences for both groups.
Figure 2 shows the planned workflow for both treatment
arms.
Primary and secondary endpoints
The primary aim of the study is to show whether a re-
duction of acute and intermediate (i.e. late-occurring
pneumonitis) radiation-induced side effects (pneumonitis
and dysphagia grade II or higher scored by Common
Terminology Criteria for Adverse Events CTC-AE 4.0)
can be achieved using proton as compared to photon
beam therapy. The primary endpoint of the study will be
the occurrence of radiation-induced side effects (CTC-AE
4.0 scoring) up to 6 months after treatment or re-planning
with another radiation modality due to infringement of
OAR or tumour coverage constraints. Secondary end-
points contain classification of severity of early and late
side effects in both groups, comparison of quality of life
Fig. 1 Flowchart of planning procedures and patient allocation
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and of treatment outcome; furthermore, dosimetric pa-
rameters and CT alterations of normal tissues at follow-up
will be compared between both groups. Quality of life will
be assessed additionally by the European Organisation for
Research and Treatment of Cancer (EORTC) question-
naires C30 and LC13 before and at the end of treatment
and at each follow-up visit. For follow-up, patients will be
interviewed via telephone 2, 4, 8 and 10 weeks after treat-
ment based on a standardised form. Clinical follow-up ex-
aminations with additional CT or FDG-PET-CT scans are
scheduled 6 weeks, 3 months and 6 months after treat-
ment. After that, follow-up will be continued outside the
trial. During therapy and at follow-up, scoring of side ef-
fects will be performed according to CTC-AE 4.0. After
that, follow-up will be continued outside the trial and
scoring of side effects will also be performed according to
CTC-AE 4.0.
The trial design and protocol adhere to Standard
Protocol items: Recommendations for Interventional
Trials (SPIRIT) criteria (www.spirit-statement.org); the
SPIRIT checklist and figure can be found as Additional
file 1: Table S1 and Additional file 2: Figure S1.
Statistics
The primary endpoint of the study is the occurrence of
acute and intermediate radiation-induced side effects,
which will be observed in randomised patient cohorts
treated with photon or proton therapy in a 1:1 ratio. For
photon therapy, the incidence of pneumonitis and dys-
phagia grade II or higher at our institution is approxi-
mately 18% and 25%, respectively, which compares
favourably with incidences in the published literature
[6, 7]. Using proton therapy, a reduction by a factor of
4–5 seems achievable [5]. Therefore, conservative esti-
mates for pneumonitis and dysphagia occurrence are
4% and 8%, respectively. Assuming that the two side ef-
fects are independent, the combined fraction of expected
side effects is 0.18 + 0.25 – 0.18 × 0.25 = 0.39 (39%) for
photon therapy and 0.04 + 0.08 – 0.04 × 0.08 = 0.12 (12%)
for proton therapy.
Using these values, the required patient number to
reveal a significant difference in the occurrence of side
effects between the two arms is calculated as 39. This
number is based on a one-sided test of proportions
with a continuity correction using a normal approxima-
tion (STATA 11.2, StataCorp LP, College Station, TX,
USA, function sampsi). The significance level was set to
0.05 and the power to 0.8. A one-sided test seems ap-
propriate since a reduced occurrence of side effects is
expected from proton treatment. Assuming a 20%
patient dropout the final number of patients per treat-
ment arm is 49.
Discussion
The aim of this prospective randomised study is to
evaluate whether radiochemotherapy for advanced-stage
NSCLC patients with protons leads to decreased
radiation-induced side effects as compared to photons.
Acute side effects are of particular importance in thor-
acic tumour sites as compared to other radiation sites.
Acute radiation toxicity is expected to decrease quality
of life of cancer patients, though mostly only temporar-
ily, and thus is currently being subordinated to poten-
tial tumour control in a curative setting. Radiation-
induced pneumonitis, however, is a potentially lethal
toxicity and can develop into chronic fibrosis, often
causing deteriorating in patients’ long-time quality of
life [8]. Exposure of the lung, and probably also the
heart, to low and intermediate radiation doses is highly
relevant for the development of pneumonitis and can
be reduced by proton therapy (see Fig. 3 for dose distri-
butions for IMRT and proton radiotherapy) [7].
Although there is a strong correlation between radi-
ation dose and local control in preclinical studies and
Fig. 2 Flowchart of both randomised treatment arms and primary endpoint
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in studies using hypofractionated stereotactic radiother-
apy or alternative treatment modification, in advanced
disease dose escalation with photons did not translate
into a survival benefit in the recently published RTOG
0617 study [2, 9–13]. It is noteworthy that in the latter
study the dose escalation was performed without accel-
eration, even though a time factor exists for locally ad-
vanced NSCLC as confirmed by the CHARTWEL study
[14]. Protons, by a better sparing of surrounding
healthy tissue, may be able to increase the dose to the
tumour without an increase in toxicity [15]. If the
present study demonstrates a decrease in toxicity for
equal-dose radiotherapy allied with protons versus pho-
tons, increasing radiation doses with protons within a
clinical trial would be the next step to achieve better
local tumour control, which may then also be related to
increased overall survival and metastasis-free survival
as shown by others [16].
Trial status
The trial is currently recruiting.
Additional files
Additional file 1: Table S1. SPIRIT 2013 checklist PRONTOX. (DOC 121 kb)
Additional file 2: Figure S1. SPIRIT 2013 figure PRONTOX. (DOC 51 kb)
Abbreviations
3D-CRT: three-dimensional conformal radiation therapy; 4D-CT: Four-dimensional
computer tomography; CT: Computer tomography; CTC-AE: Common
Terminology Criteria for Adverse Events; CTV: Clinical target volume;
FDG: Fluorodeoxyglucose; GTV: Gross tumour volume; Gy: Gray;
iGTV: Internal gross tumour volume; IMRT: Intensity-modulated radiation
therapy; MRI: Magnetic resonance imaging; NSCL: Non-small-cell lung
carcinoma; OAR: Organs at risk; PET: Positron Emission Tomography;
RBE: Relative biological effectiveness
Fig. 3 Dose distribution of one patient with locally advanced non-small cell lung cancer (NSCLC) planned with intensity-modulated radiation therapy
(IMRT) (left) or protons (right) showing lower doses to organs at risk (OAR) by proton therapy
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